Predicted protein targets (top 3)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CD274 | Q9NZQ7 | 20/20 | 0.48 |
| ▸ | PDCD1LG2 | Q9BQ51 | 18/20 | 0.48 |
| ▸ | PDCD1 | Q15116 | 2/20 | 0.46 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL29983818 | 0.97 | CD274 (0.54) | CD274PDCD1LG2PDCD1 | |
| SCHEMBL29984159 | 0.96 | CD274 (0.45) | CD274PDCD1LG2PDCD1 | |
| SCHEMBL27080181 | 0.93 | CD274 (0.50) | CD274PDCD1LG2PDCD1 | |
| SCHEMBL27080172 | 0.93 | CD274 (0.50) | CD274PDCD1LG2PDCD1 | |
| SCHEMBL29983914 | 0.89 | CD274 (0.46) | CD274PDCD1LG2PDCD1 | |
| SCHEMBL23726258 | 0.88 | CD274 (0.51) | CD274PDCD1LG2PDCD1 | |
| SCHEMBL30432925 | 0.88 | CD274 (0.51) | CD274PDCD1LG2PDCD1 | |
| SCHEMBL29983734 | 0.87 | CD274 (0.44) | CD274PDCD1LG2PDCD1 | |
| SCHEMBL27079267 | 0.85 | PDCD1LG2 (0.67) | CD274PDCD1LG2 | |
| SCHEMBL27078369 | 0.85 | PDCD1LG2 (0.67) | CD274PDCD1LG2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20240246964-A1 | SUBSTITUTED 1-ARYL-1’-HETEROARYL COMPOUNDS, SUBSTITUTED 1,1’-BIHETEROARYL COMPOUNDS, AND METHODS USING SAME | ARBUTUS BIOPHARMA CORPORATION (CA) | 2024-07-25 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20240246964-A1 | SUBSTITUTED 1-ARYL-1’-HETEROARYL COMPOUNDS, SUBSTITUTED 1,1’-BIHETEROARYL COMPOUNDS, AND METHODS USING SAME | HAVCR2, HDGF, HCCS | CD274 48/4885PDCD1LG2 163/4885PDCD1 32/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.